Texas Gov. Greg Abbott on June 11 signed a bill creating a consortium of universities, hospitals and pharmaceutical firms to conduct clinical trials on ibogaine, in hopes of receiving US Food & Drug Administration approval. The press release on the signing hails ibogaine as an "emerging treatment for neurological and mental health conditions." Lawmakers approved $50 million to support the effort, making Texas the global leader in psychedelic research investment. (Texas Tribune)


Next week, the Multidisciplinary Association for Psychedelic Studies (MAPS) will bring a host of psychedelic scientists and visionary artists together in San Jose, California for the largest conference of its kind in the U.S. in 17 years.





Recent comments
17 hours 24 min ago
6 days 23 hours ago
5 weeks 6 hours ago
8 weeks 5 days ago
12 weeks 5 days ago
13 weeks 4 days ago
23 weeks 4 days ago
27 weeks 4 days ago
28 weeks 5 days ago
28 weeks 5 days ago